title: Effect of two lipid emulsions on reversing high-dose levobupivacaine-induced reduced vasoconstriction in the rat aortas.
abstract: The goals of this study were to determine which lipid emulsion (Intralipid(®) and Lipofundin MCT/LCT(®)) is more effective in reversing high-dose levobupivacaine-induced reduced vasoconstriction in isolated rat aortas and to examine the associated cellular mechanisms with a particular focus on the endothelium. Two lipid emulsion concentration-response curves were generated using high-dose levobupivacaine-induced reduced vasoconstriction and vasodilation of isolated aortas pretreated with or without 60 mM KCl. Endothelial nitric oxide synthase (eNOS) and caveolin-1 phosphorylation were measured in rat aortic tissue treated with levobupivacaine in the presence or absence of lipid emulsion. Dichlorofluorescein oxidation, a measure of reactive oxygen species production, was measured in lipid emulsion-treated human umbilical vein endothelial cells. In levobupivacaine (0.3 mM)-induced reduced vasoconstriction of isolated aorta, the magnitude of the Intralipid(®)- and Lipofundin MCT/LCT(®)-mediated reversal was not significantly different. Lipid emulsion reversal of levobupivacaine-induced reduced vasoconstriction was greater in endothelium-intact aortas than in endothelium-denuded aortas. The two lipid emulsions similarly inhibited levobupivacaine-induced eNOS phosphorylation in aortic tissue. Pretreatment with both lipid emulsions increased dichlorofluorescein oxidation. Both Intralipid(®) and Lipofundin MCT/LCT(®) are equally effective for vascular tone recovery from high-dose levobupivacaine-induced reduced vasoconstriction. This reversal is mediated partially by decreasing nitric oxide bioavailability.
authors.affiliation: Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, Jinju, 660-702, Republic of Korea.
authors.forename: Seong-Ho
authors.initials: SH
authors.lastname: Ok
authors.forename: Chang-Shin
authors.initials: CS
authors.lastname: Park
authors.forename: Hye Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Soo Hee
authors.initials: SH
authors.lastname: Lee
authors.forename: Bo-Hwa
authors.initials: BH
authors.lastname: Choi
authors.forename: So Young
authors.initials: SY
authors.lastname: Eun
authors.forename: Kyung-Nam
authors.initials: KN
authors.lastname: Kim
authors.forename: Seong Min
authors.initials: SM
authors.lastname: Yang
authors.forename: Il-Woo
authors.initials: IW
authors.lastname: Shin
authors.forename: Mun-Jeoung
authors.initials: MJ
authors.lastname: Choi
authors.forename: Ju-Tae
authors.initials: JT
authors.lastname: Sohn
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects* / Q000502:physiology; D002045:Bupivacaine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004338:Drug Combinations; D004655:Emulsions / Q000008:administration & dosage; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects / Q000502:physiology; D006801:Humans; D000077554:Levobupivacaine; D008297:Male; D009924:Organ Culture Techniques; D010743:Phospholipids / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013012:Sorbitol / Q000008:administration & dosage*; D013024:Soybean Oil / Q000008:administration & dosage*; D016896:Treatment Outcome; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology
chemical_list: D004338:Drug Combinations; D004655:Emulsions; D005217:Fat Emulsions, Intravenous; D010743:Phospholipids; C545823:soybean oil, phospholipid emulsion; C008288:Lipofundin; D013012:Sorbitol; D013024:Soybean Oil; D000077554:Levobupivacaine; D002045:Bupivacaine